Delhi High Court Restrains Alchem Trademark Infringement

In a significant judicial development for the pharmaceutical sector, the High Court of Delhi has granted an interim injunction in favor of Alkem Laboratories Ltd. against Alchem International Pvt. Ltd., restricting the latter from using the trademark 'ALCHEM' on its medicinal products. Justice Amit Bansal, presiding over the matter, emphasized that in the interest of public safety and brand integrity, the confusion caused by phonetically identical marks in the sensitive domain of medicine cannot be ignored.

A Rivalry of Names: The Core Dispute

The legal battle originated from a suit filed by Alkem Laboratories, an established pharmaceutical giant incorporated in 1973, alleging that Alchem International’s usage of the 'ALCHEM' mark constituted both trademark infringement and passing off.

Alkem Laboratories, which holds significant registrations for the mark 'ALKEM' dating back to 1973, contended that they represent the prior adopter and user of the trademark. The dispute intensified as the defendant, Alchem International, began expanding its retail footprint and promotional activities for products under the 'ALCHEM/ALCHEM LIFE' banner—efforts the plaintiff argued were designed to capitalize on its long-standing market goodwill.

Conflicting Arguments

The defendant, Alchem International, defended its position by citing honest and concurrent use since 1985, asserting that the plaintiff's delays in bringing the suit amounted to acquiescence. They further argued that their products, primarily nutraceuticals and ayurvedic extracts, did not overlap significantly with the plaintiff's core pharmaceutical offerings, thereby minimizing the likelihood of consumer confusion.

Counsel for the plaintiff, however, countered that the defendant had not engaged in retail pharmaceutical sales until after receiving a 2005 cease-and-desist notice. They maintained that the expansion of the defendant's marketing efforts in 2017 provided fresh causes of action, and that simple business coexistence in a trade directory does not constitute an acknowledgment of competing brand rights.

Legal Analysis: The Bench’s Stance

Justice Amit Bansal observed that the defense of acquiescence fails where there is no positive encouragement by the plaintiff. Citing landmark precedents, the court reiterated that "Mere silence on the part of the plaintiff cannot amount to acquiescence." The court found that the adoption of the mark by the defendant—being fully aware of the prior existence of the plaintiff—could not be viewed as a bona fide venture.

Refining the scope, the Court highlighted that the pharmaceutical industry demands a higher standard of scrutiny. Since both entities operate within the same trade channels, the court ruled that the visual and phonetic identity of the marks created an unacceptable risk of deception for the common consumer.

Key Observations

The judgment offers critical insights into the protection of intellectual property:

• On Infringement: "The marks of the plaintiff ‘ALKEM’ and of the defendant ‘ALCHEM’ are phonetically identical and visually and structurally deceptively similar."
• On Public Interest: "Irreparable harm and injury would be caused not only to the plaintiff but also to the public at large, if the defendant is permitted to use the said mark, in respect of similar goods... which is likely to cause confusion and deception among the consumers."
• On Acquiescence: "In order to constitute acquiescence, there has to be a positive/overt act on behalf of the plaintiff. Mere silence on behalf of the plaintiff cannot amount to acquiescence."
• On Honest Adoption: "It cannot be stated that the defendant is an honest and bona fide adopter or concurrent user of the mark ‘ALCHEM’."

The Final Order

The Delhi High Court has restrained the defendant, its agents, and partners from manufacturing, marketing, or advertising any pharmaceutical or medicinal products under the brand 'ALCHEM'. However, in a balanced move, the Court carved out an exception: the defendant is permitted to continue using the 'ALCHEM' mark for the manufacturing and export of Active Pharmaceutical Ingredients (APIs), provided these products are not sold in the Indian retail market.

This ruling stands as a clear signal that the court will protect prior registrants when a defendant’s brand expansion threatens to collide with established market identity, particularly when consumer safety in the medical sector is at stake. The matter is next listed for further proceedings on 3rd December 2025.